4 results about "Adalimumab" patented technology

The present application relates to a method for preparing an antibody group and an antibody group prepared by the method, which can prepare a high-purity and high-quality desired antibody group by removing impurities without using an expensive protein A column, and in particular, can achieve process automation and greatly reduce production costs.

The invention belongs to the technical field of biological medicine, and discloses an adeno-associated virus mutant and application thereof. The adeno-associated virus mutant capable of delivering the adalimumab or the Ozorezumab nano-antibody is produced by co-transfecting a recombinant plasmid of a sequence for coding the adalimumab or the Ozorezumab nano-antibody, an auxiliary plasmid and a packaging plasmid into a cell, and the disease progress of an arthritis mouse model can be safely and effectively relieved. According to the invention, an optimal administration scheme selection is provided for research on joint specific gene therapy, and a new way is provided for clinical treatment of arthritis.

The present application belongs to the field of pharmacy, and provides an adalimumab composition, wherein aspartic acid is used as a buffer system. The adalimumab pharmaceutical composition has high physical and chemical stability, and can be stored for a long time.

The invention relates to the technical field of recombinant protein expression and cell culture, in particular to application of safflower leaf exosome-like nano-vesicles to improvement of CHO cell line recombinant protein expression quantity. Specifically, safflower leaf exosome-like nano-vesicles with a specific concentration are added into a CHO cell serum-free culture medium. Compared with a traditional safflower leaf water extract, the additive can remarkably improve the living cell density in the culture process, prolong the culture period, inhibit cell apoptosis and enhance the cell oxidation resistance. Experiments prove that the cell specificity productivity can be effectively improved, and the expression quantity of adalimumab, motuzumab and other target antibodies is remarkably increased. On the premise that the scale of the bioreactor is not enlarged, the yield of the culture medium in unit volume is increased, the consumption and production cost of the culture medium are reduced, and an innovative culture strategy is provided for efficient and economical production of the monoclonal antibody.